Cladribine Is Associated With Stable Cortical Gray Matter Lesion Burden in Multiple Sclerosis: A 7T MRI Study
These observational data suggest that cladribine therapy stabilizes cortical demyelination in MS over the first year of treatment. Overall, LME burden remained stable over 1 year; however, within-subject resolution and accrual were noted.
Authors
- Renxin Chu (ORCID: https://orcid.org/0000-0002-1668-238X)
- Maria K. Houtchens (ORCID: https://orcid.org/0000-0001-6077-0654)
- Shahamat Tauhid (ORCID: https://orcid.org/0000-0001-7198-501X)
- Youmna Jalkh
- Syed Rizvi (ORCID: https://orcid.org/0000-0001-7175-2064)
- Brian C. Healy (ORCID: https://orcid.org/0000-0001-5272-2425)
- Rohit Bakshi (ORCID: https://orcid.org/0000-0001-8601-5534)
- Farrah Jasmine Mateen (ORCID: https://orcid.org/0000-0002-4293-8115)
- Jonathan Zurawski (ORCID: https://orcid.org/0000-0002-2896-8369)
- Samar Khalil
- Molly Quattrucci
- Tarun Singhal (ORCID: https://orcid.org/0000-0001-6616-5113)
- Salvatore Napoli (ORCID: https://orcid.org/0000-0002-7713-7983)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Brown University (US)
- Massachusetts General Hospital (US)
- New England Center for Children (US)
Publication Details
- Journal
- Journal of Neuroimaging
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1111/jon.70032
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- EMD Serono